Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: Preliminary experience

Ugo De Giorgi, Giovanni Rosti, Giorgio Papiani, Michele Aieta, Francesca Fochessati, Luca Paoluzzi, Francesco Valduga, Maurizio Marangolo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Although the overall cure rate for advanced germ cell tumor (GCT) is high, the prognosis for patients with cisplatin-refractory GCT remains poor. Gemcitabine, paclitaxel, and oxaliplatin have shown significant activity as single agents in these patients. We investigated the activity and tolerance of a weekly gemcitabine, paclitaxel, oxaliplatin chemotherapy regimen. From September 2000 to February 2002, 9 patients with cisplatin-refractory GCT were treated with gemcitabine 800 mg/m2, paclitaxel 70 mg/m2, and oxaliplatin 50 mg/m2, days 1, 8, and 15, every 4 weeks. Only 1 patient stayed on schedule. In 7 patients, chemotherapy treatment was modified due to grade 3-4 hematological toxicity, whereas in another patient, who received high-dose chemotherapy 2 months before, chemotherapy was administered biweekly. In total, 21 cycles were administered with a median of 2 cycles for each patient. One patient achieved a partial remission lasting 5 months, 1 had disease stabilization for 5 months, whereas 7 had progressive disease. This chemotherapy regimen was not feasible in our patient population. Recently, oxaliplatin at full doses, but not as weekly administration, has appeared to possess activity in cisplatin-refractory GCT. Thus, we plan a phase II study protocol of the oxaliplatin and gemcitabine combination at full doses every 3 weeks.

Original languageEnglish (US)
Pages (from-to)457-460
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume27
Issue number5
DOIs
StatePublished - Oct 1 2004
Externally publishedYes

Fingerprint

oxaliplatin
gemcitabine
Germ Cell and Embryonal Neoplasms
Paclitaxel
Combination Drug Therapy
Cisplatin
Drug Therapy
Proxy

Keywords

  • Cisplatin-refractory germ cell tumor
  • Gemcitabine
  • Oxaliplatin
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor : Preliminary experience. / De Giorgi, Ugo; Rosti, Giovanni; Papiani, Giorgio; Aieta, Michele; Fochessati, Francesca; Paoluzzi, Luca; Valduga, Francesco; Marangolo, Maurizio.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, No. 5, 01.10.2004, p. 457-460.

Research output: Contribution to journalArticle

De Giorgi, Ugo ; Rosti, Giovanni ; Papiani, Giorgio ; Aieta, Michele ; Fochessati, Francesca ; Paoluzzi, Luca ; Valduga, Francesco ; Marangolo, Maurizio. / Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor : Preliminary experience. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2004 ; Vol. 27, No. 5. pp. 457-460.
@article{fbf6d5a13a69459c96e6acb0f5203051,
title = "Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: Preliminary experience",
abstract = "Although the overall cure rate for advanced germ cell tumor (GCT) is high, the prognosis for patients with cisplatin-refractory GCT remains poor. Gemcitabine, paclitaxel, and oxaliplatin have shown significant activity as single agents in these patients. We investigated the activity and tolerance of a weekly gemcitabine, paclitaxel, oxaliplatin chemotherapy regimen. From September 2000 to February 2002, 9 patients with cisplatin-refractory GCT were treated with gemcitabine 800 mg/m2, paclitaxel 70 mg/m2, and oxaliplatin 50 mg/m2, days 1, 8, and 15, every 4 weeks. Only 1 patient stayed on schedule. In 7 patients, chemotherapy treatment was modified due to grade 3-4 hematological toxicity, whereas in another patient, who received high-dose chemotherapy 2 months before, chemotherapy was administered biweekly. In total, 21 cycles were administered with a median of 2 cycles for each patient. One patient achieved a partial remission lasting 5 months, 1 had disease stabilization for 5 months, whereas 7 had progressive disease. This chemotherapy regimen was not feasible in our patient population. Recently, oxaliplatin at full doses, but not as weekly administration, has appeared to possess activity in cisplatin-refractory GCT. Thus, we plan a phase II study protocol of the oxaliplatin and gemcitabine combination at full doses every 3 weeks.",
keywords = "Cisplatin-refractory germ cell tumor, Gemcitabine, Oxaliplatin, Paclitaxel",
author = "{De Giorgi}, Ugo and Giovanni Rosti and Giorgio Papiani and Michele Aieta and Francesca Fochessati and Luca Paoluzzi and Francesco Valduga and Maurizio Marangolo",
year = "2004",
month = "10",
day = "1",
doi = "10.1097/01.coc.0000128727.40450.9e",
language = "English (US)",
volume = "27",
pages = "457--460",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor

T2 - Preliminary experience

AU - De Giorgi, Ugo

AU - Rosti, Giovanni

AU - Papiani, Giorgio

AU - Aieta, Michele

AU - Fochessati, Francesca

AU - Paoluzzi, Luca

AU - Valduga, Francesco

AU - Marangolo, Maurizio

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Although the overall cure rate for advanced germ cell tumor (GCT) is high, the prognosis for patients with cisplatin-refractory GCT remains poor. Gemcitabine, paclitaxel, and oxaliplatin have shown significant activity as single agents in these patients. We investigated the activity and tolerance of a weekly gemcitabine, paclitaxel, oxaliplatin chemotherapy regimen. From September 2000 to February 2002, 9 patients with cisplatin-refractory GCT were treated with gemcitabine 800 mg/m2, paclitaxel 70 mg/m2, and oxaliplatin 50 mg/m2, days 1, 8, and 15, every 4 weeks. Only 1 patient stayed on schedule. In 7 patients, chemotherapy treatment was modified due to grade 3-4 hematological toxicity, whereas in another patient, who received high-dose chemotherapy 2 months before, chemotherapy was administered biweekly. In total, 21 cycles were administered with a median of 2 cycles for each patient. One patient achieved a partial remission lasting 5 months, 1 had disease stabilization for 5 months, whereas 7 had progressive disease. This chemotherapy regimen was not feasible in our patient population. Recently, oxaliplatin at full doses, but not as weekly administration, has appeared to possess activity in cisplatin-refractory GCT. Thus, we plan a phase II study protocol of the oxaliplatin and gemcitabine combination at full doses every 3 weeks.

AB - Although the overall cure rate for advanced germ cell tumor (GCT) is high, the prognosis for patients with cisplatin-refractory GCT remains poor. Gemcitabine, paclitaxel, and oxaliplatin have shown significant activity as single agents in these patients. We investigated the activity and tolerance of a weekly gemcitabine, paclitaxel, oxaliplatin chemotherapy regimen. From September 2000 to February 2002, 9 patients with cisplatin-refractory GCT were treated with gemcitabine 800 mg/m2, paclitaxel 70 mg/m2, and oxaliplatin 50 mg/m2, days 1, 8, and 15, every 4 weeks. Only 1 patient stayed on schedule. In 7 patients, chemotherapy treatment was modified due to grade 3-4 hematological toxicity, whereas in another patient, who received high-dose chemotherapy 2 months before, chemotherapy was administered biweekly. In total, 21 cycles were administered with a median of 2 cycles for each patient. One patient achieved a partial remission lasting 5 months, 1 had disease stabilization for 5 months, whereas 7 had progressive disease. This chemotherapy regimen was not feasible in our patient population. Recently, oxaliplatin at full doses, but not as weekly administration, has appeared to possess activity in cisplatin-refractory GCT. Thus, we plan a phase II study protocol of the oxaliplatin and gemcitabine combination at full doses every 3 weeks.

KW - Cisplatin-refractory germ cell tumor

KW - Gemcitabine

KW - Oxaliplatin

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=5644273927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644273927&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000128727.40450.9e

DO - 10.1097/01.coc.0000128727.40450.9e

M3 - Article

C2 - 15596910

AN - SCOPUS:5644273927

VL - 27

SP - 457

EP - 460

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -